Neuralstem: An Update on Its Pipeline and Supporting Clinical Trials (CUR, Neutral, $1.00)Purpose of this Report Neuralstem: My Analysis of Phase 1 and Phase 2 Results for NSI-566 Neural Stem Cells in ALS Indicates Encouraging Signals of Efficacy (CUR, Buy, $1.25)Putting This Report in Perspective This is an extensive report that goes over the aggregate results of the phase 1 and… Neuralstem: Initial Thoughts on Just Released Encouraging Phase 2 Data on the Use of NSI-566 Stem Cells to Treat ALS. Neuralstem Will Proceed to a Potentially Registrational Trial in 2016 (CUR, Buy, $1.50)Introduction Neuralstem released this morning (September 29) new information from principal investigator Eva Feldman on phase 2 data from the use… Neuralstem: The 2015 Decline in the Stock is in Contrast to Encouraging ALS Data and an Impressive Pipeline (CUR, Buy, $1.38)Investment Background Neuralstem has been absolutely pummeled this year as the price has declined from a closing of $2.72 on December… Comments on Agenus, Neuralstem and CelldexSmithOnStocks Mailbox Neuralstem: A Closer Look at Encouraging Phase 2 Results for NSI-566 Neural Stem Cells in Treating ALS (CUR, Buy, $2.36)Observations about the Phase 2 Trial Results I spent the weekend thinking about the data released in the phase 2 trial… Neuralstem: Initial Take on Top Line Results of Phase 2 ALS Trial of NSI-566 Neural Stem Cells (CUR, Buy, $3.08)The topline data for the phase 2 trial of NSI-566 stem cells were released today. The initial stock reaction indicates… Neuralstem: When Will We See the Phase 2 Data for NSI-566 in ALS? (CUR, Buy, $3.75)Management has guided that the phase 2 data on 15 patients treated in the phase 2 trial of NSI-566 neural… Some Observations on Northwest Biotherapeutics (NWBO), Neuralstem (CUR), Cytokinetics (CYTK) and Immuno-Cellular (IMUC) from Their Presentations at BIO CEO.The BIO CEO Conference is being held in New York at the Waldorf Astoria on February 9 and 10 with… Notes from Neuralstem Presentation at Biotech Showcase Conference, January 13, 2015 (CUR, Buy, $3.09)Richard Gar, CEO of Neuralstem (CUR), made a presentation at Biotech Showcase Conference in San Francisco on January 13, 2015.… Neuralstem: An Update on Potential Catalysts for 2015 (CUR, Buy, 3.38)Overview and Investment Thinking I wrote a report on Neuralstem on August 26, 2014 in which I projected the timing of important… Neuralstem: Some Encouraging, But Very Early, Information on Chinese Ischemic Stroke Trial Using NSI-566 Stem Cells (CUR, Buy, $2.59)Purpose of This Blog I received this e-mail communication from a SmithOnStocks subscriber who has a good insight into the Chinese… Weakness in Neuralstem Caused by Seeking Alpha Article Presents a Buying Opportunity (CUR, $2.69, Buy)
This is an updated version of a blog that was published on October 20th. Neuralstem: Investigators are Very Positive on NSI-566 Results in ALS (CUR, Buy, $3.27)Investment Perspective The key investigators for the treatment of ALS with Neuralstem’s NSI-566 neural stem cells have been extremely positive in… Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)Key Points The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could… Neuralstem: Phase 1b Results for NSI-189 are Very Encouraging but It Is Early Days (CUR, Buy, $4.38, For paid subscribers)Investment Thesis on Neuralstem I continue with my long standing buy on Neuralstem that is almost entirely based on the potential… Neuralstem: Encouraging Phase 1b Data on NSI-189 (CUR, Buy, $4.35, Free content)On June 17 at the American Society of Clinical Psychopharmacology Neuralstem reported phase 1b data for its small molecule drug… Neuralstem: An In-Depth Look at NSI-189, A Novel Small Molecule Drug Being Studied in Major Depressive Disorder (CUR, Buy, $3.60, For Paid Subscribers)Investment Thesis My recommendation of Neuralstem (CUR) has been based primarily on the potential for its neural stem cells NSI-566 in… Thoughts on the Market Correction in Biotechnology StocksThis Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology… Neuralstem: Dr. Eva Feldman’s Latest Presentation on The Use of CUR’s Stem Cells in ALS (CUR, Buy, $4.04)Overview Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)Introduction The final results of the phase 1 trial of Neuralstem’s (CUR) NSI-566 spinal cord stem cells in the treatment of… SmithOnStocks Mailbox February 25, 2014I have found that there are some very smart people out there who have interesting questions and perspectives concerning my… The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)Back From BIO CEO Conference I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria… San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)What SmithOnStocks Is All About Neuralstem: Sizing Up Potential Key Events of 2014 (CUR, $3.42)Investment Thesis and Overview Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)Thoughts on the Stock Price SmithOnStocks Opines on Biotechnology Stocks, June 10, 2013Introduction SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013Overview of This Week's Report SmithOnStocks Opines on Biotechnology Stocks, May 28, 2013Introduction Neuralstem: Update on Phase I Trial of Neural Stem Cells in ALS is Encouraging (CUR, $1.45)Purpose of Report SmithOnStocks Opines on Stocks May 19, EditionOne Approach for Investing in Emerging Biotechnology Stocks |